PHILADELPHIA – Compared to oncology, chronic diseases such as cardiovascular disease, diabetes and dementia represent much more substantial costs to the overall U.S. health care system, yet investment and R&D innovation in those areas has been on a steady decline over the past decade or so, according to research compiled by the Biotechnology Innovation Organization (BIO).